RHYTHM PHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
RYTM$113.95+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine months ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(146,306) | $(149,034) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 74,180 | 47,552 |
| Depreciation and amortization | 751 | 1,066 |
| Non-cash interest expense | 13,611 | 15,968 |
| Non-cash accretion & amortization of short-term investments | (3,593) | (4,661) |
| Non-cash rent expense | 355 | 319 |
| Change in fair value of embedded derivative liability | 720 | (780) |
| Foreign currency (gain) loss | (121) | (439) |
| Other non-cash items | 746 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (13,039) | (13,745) |
| Inventory | (6,179) | (2,547) |
| Prepaid expenses and other current assets | (1,053) | (3,620) |
| Deferred revenue | (194) | (1,286) |
| Other long-term assets, net | 16 | 284 |
| Accounts payable, accrued expenses and other liabilities | 23,707 | 20,637 |
| Net cash used in operating activities | (56,399) | (90,286) |
| Investing activities | ||
| Purchases of short-term investments | (176,671) | (328,322) |
| Maturities of short-term investments | 232,130 | 200,822 |
| Acquisition of IPR&D assets | — | (40,000) |
| Purchases of property and equipment | (500) | — |
| Net cash provided by (used in) investing activities | 54,959 | (167,500) |
| Financing activities | ||
| Repayment of deferred royalty obligation | (19,127) | (14,517) |
| Proceeds from issuance of common stock upon completion of public offering, net of offering costs | — | 188,655 |
| Proceeds from the exercise of stock options | 19,834 | 11,155 |
| Tax withholding on vesting of restricted stock | (14,220) | — |
| Proceeds from issuance of common stock from ESPP | 2,157 | 1,583 |
| Dividend payment for Series A Preferred Stock | (1,457) | — |
| Proceeds from ATM equity offering | — | 34,035 |
| Net cash (used in) provided by financing activities | (12,813) | 220,911 |
| Effect of exchange rates on cash | 692 | 23 |
| Net decrease in cash, cash equivalents and restricted cash | (13,561) | (36,852) |
| Cash, cash equivalents and restricted cash at beginning of period | 54,823 | 89,601 |
| Cash, cash equivalents and restricted cash at end of period | $41,262 | $52,749 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Accretion of preferred stock dividends | $3,153 | $4,046 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.